Similar articles

• Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant.

  Cariou R, Tobelem G, Soria C, Caen J. Cariou R, et al. N Engl J Med. 1986 May 1;314(18):1193-4. doi: 10.1056/NEJM198605013141817. N Engl J Med. 1986. PMID: 3083259 No abstract available.
• The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

  Anderson NE, Ali MR. Anderson NE, et al. Ann Rheum Dis. 1984 Oct;43(5):760-3. doi: 10.1136/ard.43.5.760. Ann Rheum Dis. 1984. PMID: 6437349 Free PMC article.
• Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant.

  Lo SC, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG. Lo SC, et al. Br J Haematol. 1990 Nov;76(3):380-6. doi: 10.1111/j.1365-2141.1990.tb06372.x. Br J Haematol. 1990. PMID: 2175638
• SerpinC1/Antithrombin III in kidney-related diseases.

  Lu Z, Wang F, Liang M. Lu Z, et al. Clin Sci (Lond). 2017 May 1;131(9):823-831. doi: 10.1042/CS20160669. Clin Sci (Lond). 2017. PMID: 28424376 Free PMC article. Review.
• The hypercoagulable states.

  Schafer AI. Schafer AI. Ann Intern Med. 1985 Jun;102(6):814-28. doi: 10.7326/0003-4819-102-6-814. Ann Intern Med. 1985. PMID: 3158262 Review.